UNSPSC 51312303: Chlorphenoxamine

This classification denotes a histamine-1 receptor antagonist with the molecular formula C18H22ClNO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3UVD77BP8R, chemically known as 2-(1-(p-chlorophenyl)-1-phenylethoxy)-n,n-dimethylethylamine but generally known as chlorphenoxamine, which bears US NIH Compound Identifier 6475. European Medicines Agency schedules Chlorphenoxamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06204MIG.

UNSPSC 51312303 Chlorphenoxamine is a Commodity code that captures pharmaceutical products procured by state and local health agencies, though recent solicitations tagged to this code show a broader pharmaceutical procurement landscape than the single-product code name suggests. State and local governments are buying generic multi-source pharmaceuticals, over-the-counter products, naloxone and drug deactivation systems, and exploring direct-to-manufacturer prescription programs through this classification. Issuing bodies include state health departments (Texas Health and Human Services Commission), state procurement offices administering cooperative purchasing vehicles (Minnesota Department of Administration's Office of State Procurement), county health agencies (Seminole County, Florida), and multistate cooperative purchasing alliances (MMCAP). The work spans product supply agreements with manufacturers, wholesaler distribution arrangements, and quarterly delivery of emergency response pharmaceuticals to county facilities.

Recent activity concentrates in Texas, Minnesota, Florida, and other MMCAP member states. The Minnesota Department of Administration issued an RFP (S1070000015802) on January 20, 2026 for generic multi-source pharmaceuticals and OTC products through MMCAP, with proposals due March 26, 2026 and awarded products effective July 1, 2026; vendors must supply through authorized wholesalers and maintain cGMP and DSCSA compliance with commercial general liability insurance of at least $5 million per occurrence. Seminole County, Florida released an IFB (IFB60459723LAS) on June 30, 2026 for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a response deadline of July 26, 2023, featuring a two-year initial term with one-year renewal option and FEMA funding compliance requirements. The Texas HHS Commission posted an RFI (HHS0017013) on April 3, 2026 to gather vendor capability and market intelligence on a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, signaling future formal competitive solicitations for direct state-to-manufacturer contracting outside traditional PBM and GPO channels.